Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 6603114267
Loop profile: 567255

Keywords

PP2A, mNCX, Neurodegenerative diseases, Phosphatases, P2X7 receptors, Medicinal and Pharmaceutical Chemistry

Countries

Spain

Activities

Collapse all

Employment (5)

Universidad Rey Juan Carlos - Campus de Alcorcón: Alcorcon, Madrid, ES

2022-12-01 to present | Profesor Contratado Doctor (Lecturer) (Ciencias Básicas de la Salud)
Employment
Source: Self-asserted source
Cristobal de los Rios

Instituto de Investigación Sanitaria del Hospital Universitario de la Princesa: Madrid, Madrid, ES

2011-01-01 to 2022-11-30 | Principal Researcher (Servicio de Farmacología Clínica)
Employment
Source: Self-asserted source
Cristobal de los Rios

Universidad de Alcalá de Henares: Madrid, Madrid, ES

2009-02-01 to 2010-12-31 | Research fellow (Organic Chemistry)
Employment
Source: Self-asserted source
Cristobal de los Rios

Universidad Autónoma de Madrid: Madrid, Madrid, ES

2005-11-07 to 2008-11-07 | "Juan de la Cierva" researcher (Pharmacology)
Employment
Source: Self-asserted source
Cristobal de los Rios

Colorado State University: Fort Collins, CO, US

2003-01-13 to 2005-05-17 | Research fellow (Chemistry)
Employment
Source: Self-asserted source
Cristobal de los Rios

Education and qualifications (3)

Universidad Autónoma de Madrid: Madrid, Madrid, ES

1999-06-01 to 2003-01-10 | PhD (Pharmacology)
Education
Source: Self-asserted source
Cristobal de los Rios

Universidad Autónoma de Madrid: Madrid, Madrid, ES

1996-10-01 to 1998-09-30 | Organic Chemistry/MSc (Organic Chemistry)
Education
Source: Self-asserted source
Cristobal de los Rios

Universidad Autónoma de Madrid: Madrid, Madrid, ES

1991-10-01 to 1996-06-23 | Chemistry/Bachelor (Organic Chemistry)
Education
Source: Self-asserted source
Cristobal de los Rios

Funding (5)

DISEÑO, SINTESIS Y EVALUACION DE FARMACOS ANTAGONISTAS DE RECEPTORES P2X7 Y ACTIVADORES DE LA FOSFATASA PP2A: NUEVA TERAPIA MULTIDIANA PARA ENFERMEDADES NEURODEGENERATIVAS

2023-07 to 2025-06 | Award
Agencia Estatal de Investigación (Madrid, ES)
GRANT_NUMBER:

CNS2022-135290
Source: Self-asserted source
Cristobal de los Rios

Potencial terapéutico del mantenimiento de la actividad de la proteína fosfatasa 2A: Una alternativa farmacológica para el tratamiento de las enfermedades neurodegenerativas y el cáncer

2020-01-01 to 2022-12-31 | Grant
Instituto de Salud Carlos III (Madrid, ES)
URL: https://app.dimensions.ai/details/grant/grant.9668035
GRANT_NUMBER: PI19/01724
Source: Self-asserted source
Cristobal de los Rios via DimensionsWizard

El intercambiador sodio/calcio mitocondrial como diana terapeutica para el desarrollo de fármacos innovadores para el tratamiento de enfermedades neurodegenerativas e ictus

2017-01 to 2019-12 | Award
Instituto de Salud Carlos III (Madrid, ES)
GRANT_NUMBER:

PI16/01041
Source: Self-asserted source
Cristobal de los Rios

La proteína fosfatasa 2A como diana terapéutica para el desarrollo de nuevos fármacos para el tratamiento de enfermedades neurodegeneratativas

2014-01 to 2016-12 | Grant
Instituto de Salud Carlos III (Madrid, ES)
GRANT_NUMBER:

PI13/00789
Source: Self-asserted source
Cristobal de los Rios

The CALHM1 channel and its Alzheimer´s disease-linked mutated form P86L-CALHM1. A new biological target for the finding of neuroprotective drugs

2011-11 to 2014-03 | Grant
Instituto de Salud Carlos III (Madrid, ES)
GRANT_NUMBER:

CP10/00531
Source: Self-asserted source
Cristobal de los Rios

Peer review (46 reviews for 15 publications/grants)

Review activity for Antioxidants. (1)
Review activity for Biomedicine & pharmacotherapy. (1)
Review activity for Biomolecules. (3)
Review activity for Bioscience reports. (1)
Review activity for Brain research. (1)
Review activity for Cellular and molecular life sciences (2)
Review activity for Drug design, development and therapy (1)
Review activity for European journal of medicinal chemistry. (1)
Review activity for European journal of medicinal chemistry. (3)
Review activity for Future medicinal chemistry. (2)
Review activity for Journal of medicinal chemistry. (21)
Review activity for Journal of molecular structure. (4)
Review activity for Molecules. (2)
Review activity for Pharmaceuticals. (2)
Review activity for Toxicology and applied pharmacology. (1)
How many people are using ORCID?